The European Medicines Agency accepted ChemoCentryx Inc.'s (Nasdaq: CCXI) Conditional Marketing Authorization application for avacopan which triggered a milestone payment of $50 million from Vifor Fresenius Medical Care Renal Pharma. The stock price soared $2.44 to close at $8.63.
EMA accepts application for ChemoCentryx's avacopan
January 04, 2018 at 17:26 PM EST
